EdenteV1, PascalFrancis, Corpus, bibRecord, 000334

Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs

Identifieur interne : 000334 ( PascalFrancis/Corpus ); précédent : 000333; suivant : 000335

Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs

Auteurs : Ulf M. E. Wikesjö ; Andreas V. Xiropaidis ; Mohammed Qahash ; WON HEE LIM ; Rachel G. Sorensen ; Michael D. Rohrer ; John M. Wozney ; Jan Hall

Source :

Journal of clinical periodontology [ 0303-6979 ] ; 2008.

RBID : Pascal:08-0513726

Descripteurs français

Pascal (Inist)
- Os, Protéine recombinante, Homme, Titane, Implant, Postérieur, Mandibule, Animal, Chien, Protéine morphogénétique osseuse, Dent, Voie orale, Génie tissulaire, Etude expérimentale, Dentisterie, Protéine BMP-2, Chirurgie maxillofaciale.

English descriptors

KwdEn :
- Animal, Bone, Bone morphogenetic protein, Bone morphogenetic protein-2, Dentistry, Dog, Experimental study, Human, Implant, Mandible, Maxillofacial surgery, Oral administration, Posterior, Recombinant protein, Tissue engineering, Titanium, Tooth.

Abstract

Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone re-modelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3 ± 10.8% versus 71.7 ± 7.8%, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4 ± 10.6% versus 68.2 ± 11.0%,p<0.03], Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0303-6979`
A03		`1`		`@0 J. clin. periodontol.`
A05				`@2 35`
A06				`@2 11`
A08	`01`	`1`	`ENG`	`@1 Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs`
A11	`01`	`1`		`@1 WIKESJÖ (Ulf M. E.)`
A11	`02`	`1`		`@1 XIROPAIDIS (Andreas V.)`
A11	`03`	`1`		`@1 QAHASH (Mohammed)`
A11	`04`	`1`		`@1 WON HEE LIM`
A11	`05`	`1`		`@1 SORENSEN (Rachel G.)`
A11	`06`	`1`		`@1 ROHRER (Michael D.)`
A11	`07`	`1`		`@1 WOZNEY (John M.)`
A11	`08`	`1`		`@1 HALL (Jan)`
A14	`01`			`@1 Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry @2 Augusta, GA @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 Women's Health and Musculoskeletal Biology, Wyeth Research @2 Cambridge, MA @3 USA @Z 5 aut. @Z 7 aut.`
A14	`03`			`@1 Division of Oral and Maxillofacial Pathology, University of Minnesota School of Dentistry @2 Minneapolis, MN @3 USA @Z 6 aut.`
A14	`04`			`@1 Research & Development, Nobel Biocare AB @2 Göteborg @3 SWE @Z 8 aut.`
A20				`@1 985-991`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16273 @5 354000184242270090`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 1/2 p.`
A47	`01`	`1`		`@0 08-0513726`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of clinical periodontology`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone re-modelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3 ± 10.8% versus 71.7 ± 7.8%, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4 ± 10.6% versus 68.2 ± 11.0%,p<0.03], Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.
C02	`01`	`X`		`@0 002B25C02`
C03	`01`	`X`	`FRE`	`@0 Os @5 07`
C03	`01`	`X`	`ENG`	`@0 Bone @5 07`
C03	`01`	`X`	`SPA`	`@0 Hueso @5 07`
C03	`02`	`X`	`FRE`	`@0 Protéine recombinante @5 08`
C03	`02`	`X`	`ENG`	`@0 Recombinant protein @5 08`
C03	`02`	`X`	`SPA`	`@0 Proteína recombinante @5 08`
C03	`03`	`X`	`FRE`	`@0 Homme @5 09`
C03	`03`	`X`	`ENG`	`@0 Human @5 09`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 09`
C03	`04`	`X`	`FRE`	`@0 Titane @2 NC @5 13`
C03	`04`	`X`	`ENG`	`@0 Titanium @2 NC @5 13`
C03	`04`	`X`	`SPA`	`@0 Titanio @2 NC @5 13`
C03	`05`	`X`	`FRE`	`@0 Implant @5 14`
C03	`05`	`X`	`ENG`	`@0 Implant @5 14`
C03	`05`	`X`	`SPA`	`@0 Implante @5 14`
C03	`06`	`X`	`FRE`	`@0 Postérieur @5 15`
C03	`06`	`X`	`ENG`	`@0 Posterior @5 15`
C03	`06`	`X`	`SPA`	`@0 Posterior @5 15`
C03	`07`	`X`	`FRE`	`@0 Mandibule @5 16`
C03	`07`	`X`	`ENG`	`@0 Mandible @5 16`
C03	`07`	`X`	`SPA`	`@0 Mandíbula @5 16`
C03	`08`	`X`	`FRE`	`@0 Animal @5 17`
C03	`08`	`X`	`ENG`	`@0 Animal @5 17`
C03	`08`	`X`	`SPA`	`@0 Animal @5 17`
C03	`09`	`X`	`FRE`	`@0 Chien @5 18`
C03	`09`	`X`	`ENG`	`@0 Dog @5 18`
C03	`09`	`X`	`SPA`	`@0 Perro @5 18`
C03	`10`	`X`	`FRE`	`@0 Protéine morphogénétique osseuse @5 19`
C03	`10`	`X`	`ENG`	`@0 Bone morphogenetic protein @5 19`
C03	`10`	`X`	`SPA`	`@0 Proteína morfogenética ósea @5 19`
C03	`11`	`X`	`FRE`	`@0 Dent @5 20`
C03	`11`	`X`	`ENG`	`@0 Tooth @5 20`
C03	`11`	`X`	`SPA`	`@0 Diente @5 20`
C03	`12`	`X`	`FRE`	`@0 Voie orale @5 21`
C03	`12`	`X`	`ENG`	`@0 Oral administration @5 21`
C03	`12`	`X`	`SPA`	`@0 Vía oral @5 21`
C03	`13`	`X`	`FRE`	`@0 Génie tissulaire @5 22`
C03	`13`	`X`	`ENG`	`@0 Tissue engineering @5 22`
C03	`13`	`X`	`SPA`	`@0 Ingeniería de tejidos @5 22`
C03	`14`	`X`	`FRE`	`@0 Etude expérimentale @5 23`
C03	`14`	`X`	`ENG`	`@0 Experimental study @5 23`
C03	`14`	`X`	`SPA`	`@0 Estudio experimental @5 23`
C03	`15`	`X`	`FRE`	`@0 Dentisterie @5 30`
C03	`15`	`X`	`ENG`	`@0 Dentistry @5 30`
C03	`15`	`X`	`SPA`	`@0 Odontología @5 30`
C03	`16`	`X`	`FRE`	`@0 Protéine BMP-2 @4 CD @5 96`
C03	`16`	`X`	`ENG`	`@0 Bone morphogenetic protein-2 @4 CD @5 96`
C03	`17`	`X`	`FRE`	`@0 Chirurgie maxillofaciale @4 CD @5 97`
C03	`17`	`X`	`ENG`	`@0 Maxillofacial surgery @4 CD @5 97`
C07	`01`	`X`	`FRE`	`@0 Fissipedia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Fissipedia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Fissipedia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Carnivora @2 NS`
C07	`02`	`X`	`ENG`	`@0 Carnivora @2 NS`
C07	`02`	`X`	`SPA`	`@0 Carnivora @2 NS`
C07	`03`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`04`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`SPA`	`@0 Vertebrata @2 NS`
N21				`@1 336`

Format Inist (serveur)

NO :	PASCAL 08-0513726 INIST
ET :	Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs
AU :	WIKESJÖ (Ulf M. E.); XIROPAIDIS (Andreas V.); QAHASH (Mohammed); WON HEE LIM; SORENSEN (Rachel G.); ROHRER (Michael D.); WOZNEY (John M.); HALL (Jan)
AF :	Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry/Augusta, GA/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut.); Women's Health and Musculoskeletal Biology, Wyeth Research/Cambridge, MA/Etats-Unis (5 aut., 7 aut.); Division of Oral and Maxillofacial Pathology, University of Minnesota School of Dentistry/Minneapolis, MN/Etats-Unis (6 aut.); Research & Development, Nobel Biocare AB/Göteborg/Suède (8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of clinical periodontology; ISSN 0303-6979; Royaume-Uni; Da. 2008; Vol. 35; No. 11; Pp. 985-991; Bibl. 1/2 p.
LA :	Anglais
EA :	Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone re-modelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3 ± 10.8% versus 71.7 ± 7.8%, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4 ± 10.6% versus 68.2 ± 11.0%,p<0.03], Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.
CC :	002B25C02
FD :	Os; Protéine recombinante; Homme; Titane; Implant; Postérieur; Mandibule; Animal; Chien; Protéine morphogénétique osseuse; Dent; Voie orale; Génie tissulaire; Etude expérimentale; Dentisterie; Protéine BMP-2; Chirurgie maxillofaciale
FG :	Fissipedia; Carnivora; Mammalia; Vertebrata
ED :	Bone; Recombinant protein; Human; Titanium; Implant; Posterior; Mandible; Animal; Dog; Bone morphogenetic protein; Tooth; Oral administration; Tissue engineering; Experimental study; Dentistry; Bone morphogenetic protein-2; Maxillofacial surgery
EG :	Fissipedia; Carnivora; Mammalia; Vertebrata
SD :	Hueso; Proteína recombinante; Hombre; Titanio; Implante; Posterior; Mandíbula; Animal; Perro; Proteína morfogenética ósea; Diente; Vía oral; Ingeniería de tejidos; Estudio experimental; Odontología
LO :	INIST-16273.354000184242270090
ID :	08-0513726

Links to Exploration step

Pascal:08-0513726

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs</title>
<author><name sortKey="Wikesjo, Ulf M E" sort="Wikesjo, Ulf M E" uniqKey="Wikesjo U" first="Ulf M. E." last="Wikesjö">Ulf M. E. Wikesjö</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry</s1>
<s2>Augusta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiropaidis, Andreas V" sort="Xiropaidis, Andreas V" uniqKey="Xiropaidis A" first="Andreas V." last="Xiropaidis">Andreas V. Xiropaidis</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry</s1>
<s2>Augusta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qahash, Mohammed" sort="Qahash, Mohammed" uniqKey="Qahash M" first="Mohammed" last="Qahash">Mohammed Qahash</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry</s1>
<s2>Augusta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Won Hee Lim" sort="Won Hee Lim" uniqKey="Won Hee Lim" last="Won Hee Lim">WON HEE LIM</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry</s1>
<s2>Augusta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sorensen, Rachel G" sort="Sorensen, Rachel G" uniqKey="Sorensen R" first="Rachel G." last="Sorensen">Rachel G. Sorensen</name>
<affiliation><inist:fA14 i1="02"><s1>Women's Health and Musculoskeletal Biology, Wyeth Research</s1>
<s2>Cambridge, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rohrer, Michael D" sort="Rohrer, Michael D" uniqKey="Rohrer M" first="Michael D." last="Rohrer">Michael D. Rohrer</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Oral and Maxillofacial Pathology, University of Minnesota School of Dentistry</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wozney, John M" sort="Wozney, John M" uniqKey="Wozney J" first="John M." last="Wozney">John M. Wozney</name>
<affiliation><inist:fA14 i1="02"><s1>Women's Health and Musculoskeletal Biology, Wyeth Research</s1>
<s2>Cambridge, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hall, Jan" sort="Hall, Jan" uniqKey="Hall J" first="Jan" last="Hall">Jan Hall</name>
<affiliation><inist:fA14 i1="04"><s1>Research & Development, Nobel Biocare AB</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0513726</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0513726 INIST</idno>
<idno type="RBID">Pascal:08-0513726</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000334</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs</title>
<author><name sortKey="Wikesjo, Ulf M E" sort="Wikesjo, Ulf M E" uniqKey="Wikesjo U" first="Ulf M. E." last="Wikesjö">Ulf M. E. Wikesjö</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry</s1>
<s2>Augusta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiropaidis, Andreas V" sort="Xiropaidis, Andreas V" uniqKey="Xiropaidis A" first="Andreas V." last="Xiropaidis">Andreas V. Xiropaidis</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry</s1>
<s2>Augusta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qahash, Mohammed" sort="Qahash, Mohammed" uniqKey="Qahash M" first="Mohammed" last="Qahash">Mohammed Qahash</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry</s1>
<s2>Augusta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Won Hee Lim" sort="Won Hee Lim" uniqKey="Won Hee Lim" last="Won Hee Lim">WON HEE LIM</name>
<affiliation><inist:fA14 i1="01"><s1>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry</s1>
<s2>Augusta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sorensen, Rachel G" sort="Sorensen, Rachel G" uniqKey="Sorensen R" first="Rachel G." last="Sorensen">Rachel G. Sorensen</name>
<affiliation><inist:fA14 i1="02"><s1>Women's Health and Musculoskeletal Biology, Wyeth Research</s1>
<s2>Cambridge, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rohrer, Michael D" sort="Rohrer, Michael D" uniqKey="Rohrer M" first="Michael D." last="Rohrer">Michael D. Rohrer</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Oral and Maxillofacial Pathology, University of Minnesota School of Dentistry</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wozney, John M" sort="Wozney, John M" uniqKey="Wozney J" first="John M." last="Wozney">John M. Wozney</name>
<affiliation><inist:fA14 i1="02"><s1>Women's Health and Musculoskeletal Biology, Wyeth Research</s1>
<s2>Cambridge, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hall, Jan" sort="Hall, Jan" uniqKey="Hall J" first="Jan" last="Hall">Jan Hall</name>
<affiliation><inist:fA14 i1="04"><s1>Research & Development, Nobel Biocare AB</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical periodontology</title>
<title level="j" type="abbreviated">J. clin. periodontol.</title>
<idno type="ISSN">0303-6979</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical periodontology</title>
<title level="j" type="abbreviated">J. clin. periodontol.</title>
<idno type="ISSN">0303-6979</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Bone</term>
<term>Bone morphogenetic protein</term>
<term>Bone morphogenetic protein-2</term>
<term>Dentistry</term>
<term>Dog</term>
<term>Experimental study</term>
<term>Human</term>
<term>Implant</term>
<term>Mandible</term>
<term>Maxillofacial surgery</term>
<term>Oral administration</term>
<term>Posterior</term>
<term>Recombinant protein</term>
<term>Tissue engineering</term>
<term>Titanium</term>
<term>Tooth</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Os</term>
<term>Protéine recombinante</term>
<term>Homme</term>
<term>Titane</term>
<term>Implant</term>
<term>Postérieur</term>
<term>Mandibule</term>
<term>Animal</term>
<term>Chien</term>
<term>Protéine morphogénétique osseuse</term>
<term>Dent</term>
<term>Voie orale</term>
<term>Génie tissulaire</term>
<term>Etude expérimentale</term>
<term>Dentisterie</term>
<term>Protéine BMP-2</term>
<term>Chirurgie maxillofaciale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone re-modelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3 ± 10.8% versus 71.7 ± 7.8%, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4 ± 10.6% versus 68.2 ± 11.0%,p<0.03], Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0303-6979</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. periodontol.</s0>
</fA03>
<fA05><s2>35</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WIKESJÖ (Ulf M. E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>XIROPAIDIS (Andreas V.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>QAHASH (Mohammed)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WON HEE LIM</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SORENSEN (Rachel G.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ROHRER (Michael D.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WOZNEY (John M.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>HALL (Jan)</s1>
</fA11>
<fA14 i1="01"><s1>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry</s1>
<s2>Augusta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Women's Health and Musculoskeletal Biology, Wyeth Research</s1>
<s2>Cambridge, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Division of Oral and Maxillofacial Pathology, University of Minnesota School of Dentistry</s1>
<s2>Minneapolis, MN</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Research & Development, Nobel Biocare AB</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>985-991</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16273</s2>
<s5>354000184242270090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1/2 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0513726</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical periodontology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone re-modelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3 ± 10.8% versus 71.7 ± 7.8%, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4 ± 10.6% versus 68.2 ± 11.0%,p<0.03], Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B25C02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Os</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Bone</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hueso</s0>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Protéine recombinante</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Recombinant protein</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Proteína recombinante</s0>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Titane</s0>
<s2>NC</s2>
<s5>13</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Titanium</s0>
<s2>NC</s2>
<s5>13</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Titanio</s0>
<s2>NC</s2>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Implant</s0>
<s5>14</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Implant</s0>
<s5>14</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Implante</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Postérieur</s0>
<s5>15</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Posterior</s0>
<s5>15</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Posterior</s0>
<s5>15</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Mandibule</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Mandible</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Mandíbula</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Animal</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Animal</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Animal</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Chien</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Dog</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Perro</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Protéine morphogénétique osseuse</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Bone morphogenetic protein</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Proteína morfogenética ósea</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Dent</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Tooth</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Diente</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Voie orale</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Oral administration</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Vía oral</s0>
<s5>21</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Génie tissulaire</s0>
<s5>22</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Tissue engineering</s0>
<s5>22</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Ingeniería de tejidos</s0>
<s5>22</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Etude expérimentale</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Experimental study</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Estudio experimental</s0>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Dentisterie</s0>
<s5>30</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Dentistry</s0>
<s5>30</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Odontología</s0>
<s5>30</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Protéine BMP-2</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Bone morphogenetic protein-2</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Chirurgie maxillofaciale</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Maxillofacial surgery</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Fissipedia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Fissipedia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Fissipedia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Carnivora</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Carnivora</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Carnivora</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>336</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 08-0513726 INIST</NO>
<ET>Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs</ET>
<AU>WIKESJÖ (Ulf M. E.); XIROPAIDIS (Andreas V.); QAHASH (Mohammed); WON HEE LIM; SORENSEN (Rachel G.); ROHRER (Michael D.); WOZNEY (John M.); HALL (Jan)</AU>
<AF>Laboratory for Applied Periodontal & Craniofacial Regeneration, Departments of Periodontics and Oral Biology & Maxillofacial Pathology, Medical College of Georgia School of Dentistry/Augusta, GA/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut.); Women's Health and Musculoskeletal Biology, Wyeth Research/Cambridge, MA/Etats-Unis (5 aut., 7 aut.); Division of Oral and Maxillofacial Pathology, University of Minnesota School of Dentistry/Minneapolis, MN/Etats-Unis (6 aut.); Research & Development, Nobel Biocare AB/Göteborg/Suède (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of clinical periodontology; ISSN 0303-6979; Royaume-Uni; Da. 2008; Vol. 35; No. 11; Pp. 985-991; Bibl. 1/2 p.</SO>
<LA>Anglais</LA>
<EA>Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone re-modelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3 ± 10.8% versus 71.7 ± 7.8%, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4 ± 10.6% versus 68.2 ± 11.0%,p<0.03], Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.</EA>
<CC>002B25C02</CC>
<FD>Os; Protéine recombinante; Homme; Titane; Implant; Postérieur; Mandibule; Animal; Chien; Protéine morphogénétique osseuse; Dent; Voie orale; Génie tissulaire; Etude expérimentale; Dentisterie; Protéine BMP-2; Chirurgie maxillofaciale</FD>
<FG>Fissipedia; Carnivora; Mammalia; Vertebrata</FG>
<ED>Bone; Recombinant protein; Human; Titanium; Implant; Posterior; Mandible; Animal; Dog; Bone morphogenetic protein; Tooth; Oral administration; Tissue engineering; Experimental study; Dentistry; Bone morphogenetic protein-2; Maxillofacial surgery</ED>
<EG>Fissipedia; Carnivora; Mammalia; Vertebrata</EG>
<SD>Hueso; Proteína recombinante; Hombre; Titanio; Implante; Posterior; Mandíbula; Animal; Perro; Proteína morfogenética ósea; Diente; Vía oral; Ingeniería de tejidos; Estudio experimental; Odontología</SD>
<LO>INIST-16273.354000184242270090</LO>
<ID>08-0513726</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000334 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000334 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    EdenteV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0513726
   |texte=   Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Dec 4 11:02:15 2017. Site generation: Tue Sep 29 19:14:38 2020

	Serveur d'exploration sur le patient édenté (maquette)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le patient édenté (maquette)

Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs

Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri